Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

Go back to Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) Delayed: 28.37 +0.09 (0.32%)
Previous Close $28.28    52 Week High $37.39 
Open $28.42    52 Week Low $28.25 
Day High $28.50    P/E 17.19 
Day Low $28.28    EPS $1.65 
Volume 6,124,763       

Pfizer Inc. (NYSE: PFE) Delayed: 28.37 +0.09 (0.32%)
Previous Close $28.28    52 Week High $37.39 
Open $28.42    52 Week Low $28.25 
Day High $28.50    P/E 17.19 
Day Low $28.28    EPS $1.65 
Volume 6,124,763       

Sangamo Biosciences, Inc. (NASDAQ: SGMO) Delayed: 0.18 --0 (-0%)
Previous Close $0.18    52 Week High $9.91 
Open $0.18    52 Week Low $3.10 
Day High $0.18    P/E N/A 
Day Low $0.18    EPS $-0.48 
Volume 5,000